Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

Submitted by amarin on Wed, 04/19/2023 - 12:01
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin’s senior management team to discuss the Company’s first quarter 2023

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

Submitted by amarin on Mon, 04/17/2023 - 11:00
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S.

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

Submitted by amarin on Mon, 04/17/2023 - 11:00
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S.

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

Submitted by amarin on Tue, 04/04/2023 - 12:01
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- -- Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

Submitted by amarin on Tue, 04/04/2023 - 12:01
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- -- Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

Submitted by amarin on Thu, 03/16/2023 - 12:02
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today released the following statement:

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

Submitted by amarin on Thu, 03/16/2023 - 12:02
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today released the following statement:

Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

Submitted by amarin on Mon, 03/06/2023 - 13:00
--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -– DUBLIN, Ireland and BRIDGEWATER, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new in vitro